Bennett, M.G.A.; Meakin, A.S.; Botting-Lawford, K.J.; Niu, Y.; Ford, S.G.; Murphy, M.P.; Wiese, M.D.; Giussani, D.A.; Morrison, J.L.
Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone. Pharmaceutics 2025, 17, 285.
https://doi.org/10.3390/pharmaceutics17030285
AMA Style
Bennett MGA, Meakin AS, Botting-Lawford KJ, Niu Y, Ford SG, Murphy MP, Wiese MD, Giussani DA, Morrison JL.
Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone. Pharmaceutics. 2025; 17(3):285.
https://doi.org/10.3390/pharmaceutics17030285
Chicago/Turabian Style
Bennett, Millicent G. A., Ashley S. Meakin, Kimberley J. Botting-Lawford, Youguo Niu, Sage G. Ford, Michael P. Murphy, Michael D. Wiese, Dino A. Giussani, and Janna L. Morrison.
2025. "Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone" Pharmaceutics 17, no. 3: 285.
https://doi.org/10.3390/pharmaceutics17030285
APA Style
Bennett, M. G. A., Meakin, A. S., Botting-Lawford, K. J., Niu, Y., Ford, S. G., Murphy, M. P., Wiese, M. D., Giussani, D. A., & Morrison, J. L.
(2025). Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone. Pharmaceutics, 17(3), 285.
https://doi.org/10.3390/pharmaceutics17030285
